25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Lyra Therapeutics Inc
Buy, Hold or Sell?

Let's analyze Lyra Therapeutics Inc together

I guess you are interested in Lyra Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Lyra Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Lyra Therapeutics Inc

I send you an email if I find something interesting about Lyra Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Lyra Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Lyra Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.47
Expected worth in 1 year
$-0.56
How sure are you?
26.3%

+ What do you gain per year?

Total Gains per Share
$-1.03
Return On Investment
-484.9%

For what price can you sell your share?

Current Price per Share
$0.21
Expected price per share
$0.1625 - $0.28
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Lyra Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$0.21
Intrinsic Value Per Share
$-23.05 - $-27.39
Total Value Per Share
$-22.58 - $-26.91

2.2. Growth of Lyra Therapeutics Inc (5 min.)




Is Lyra Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$30.9m$84.6m-$14.1m-20.0%

How much money is Lyra Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$25.3m-$15.2m-$10.1m-40.0%
Net Profit Margin-6,381.7%-35,220.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Lyra Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#495 / 949

Most Revenue
#564 / 949

Most Profit
#728 / 949

Most Efficient
#850 / 949
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Lyra Therapeutics Inc?

Welcome investor! Lyra Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Lyra Therapeutics Inc.

First you should know what it really means to hold a share of Lyra Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Lyra Therapeutics Inc is $0.213. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Lyra Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Lyra Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.47. Based on the TTM, the Book Value Change Per Share is $-0.26 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Lyra Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.74-345.2%-0.39-181.8%-0.23-108.4%-0.20-95.7%-0.20-95.7%
Usd Book Value Change Per Share-0.71-333.7%-0.26-121.2%-0.05-22.3%0.0211.7%0.0211.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.71-333.7%-0.26-121.2%-0.05-22.3%0.0211.7%0.0211.7%
Usd Price Per Share0.28-3.91-3.57-5.61-5.61-
Price to Earnings Ratio-0.09--3.59--3.91--10.36--10.36-
Price-to-Total Gains Ratio-0.39-3.45--8.90--31.66--31.66-
Price to Book Ratio0.58-3.18-2.70-5.53-5.53-
Price-to-Total Gains Ratio-0.39-3.45--8.90--31.66--31.66-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.213
Number of shares4694
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.260.02
Usd Total Gains Per Share-0.260.02
Gains per Quarter (4694 shares)-1,211.95116.91
Gains per Year (4694 shares)-4,847.80467.64
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-4848-48580468458
20-9696-97060935926
30-14543-14554014031394
40-19391-19402018711862
50-24239-24250023382330
60-29087-29098028062798
70-33935-33946032743266
80-38782-38794037413734
90-43630-43642042094202
100-48478-48490046764670

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.019.00.00.0%0.019.00.00.0%0.019.00.00.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.014.00.026.3%5.014.00.026.3%5.014.00.026.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.019.00.0%0.00.019.00.0%0.00.019.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.014.00.026.3%5.014.00.026.3%5.014.00.026.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Lyra Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.711-0.258-64%-0.048-93%0.025-2954%0.025-2954%
Book Value Per Share--0.4731.078-56%1.293-63%0.876-46%0.876-46%
Current Ratio--3.6024.796-25%7.397-51%8.542-58%8.542-58%
Debt To Asset Ratio--0.6720.450+50%0.249+170%0.483+39%0.483+39%
Debt To Equity Ratio--2.0530.976+110%0.335+514%0.464+343%0.464+343%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--22005692.903291739293.226-92%307511527.250-93%466539260.688-95%466539260.688-95%
Eps---0.735-0.387-47%-0.231-69%-0.204-72%-0.204-72%
Ev To Ebitda Ratio---0.312-3.921+1159%-5.390+1630%-13.088+4101%-13.088+4101%
Ev To Sales Ratio--9.200257.907-96%1706.926-99%infnan%infnan%
Free Cash Flow Per Share---0.308-0.301-2%-0.204-34%-0.168-46%-0.168-46%
Free Cash Flow To Equity Per Share---0.310-0.198-36%-0.393+27%-0.038-88%-0.038-88%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---27.385--------
Intrinsic Value_10Y_min---23.055--------
Intrinsic Value_1Y_max---1.165--------
Intrinsic Value_1Y_min---1.143--------
Intrinsic Value_3Y_max---4.704--------
Intrinsic Value_3Y_min---4.466--------
Intrinsic Value_5Y_max---9.694--------
Intrinsic Value_5Y_min---8.894--------
Market Cap13942277.100-30%18112692.903256045542.976-93%233516777.250-92%367283443.721-95%367283443.721-95%
Net Profit Margin---80.487-63.817-21%-352.200+338%-133.666+66%-133.666+66%
Operating Margin---29.774-54.414+83%-372.650+1152%-136.161+357%-136.161+357%
Operating Ratio--30.77461.129-50%355.865-91%134.293-77%134.293-77%
Pb Ratio0.450-30%0.5853.178-82%2.696-78%5.533-89%5.533-89%
Pe Ratio-0.072+23%-0.094-3.593+3719%-3.912+4058%-10.358+10910%-10.358+10910%
Price Per Share0.213-30%0.2773.912-93%3.568-92%5.611-95%5.611-95%
Price To Free Cash Flow Ratio-0.173+23%-0.224-3.292+1367%-4.627+1962%-7.095+3062%-7.095+3062%
Price To Total Gains Ratio-0.300+23%-0.3893.449-111%-8.898+2186%-31.665+8034%-31.665+8034%
Quick Ratio--5.3488.132-34%10.519-49%9.769-45%9.769-45%
Return On Assets---0.509-0.226-56%-0.137-73%-0.156-69%-0.156-69%
Return On Equity---1.554-0.550-65%-0.185-88%-0.267-83%-0.267-83%
Total Gains Per Share---0.711-0.258-64%-0.048-93%0.025-2954%0.025-2954%
Usd Book Value--30977000.00070535000.250-56%84661000.000-63%57331579.000-46%57331579.000-46%
Usd Book Value Change Per Share---0.711-0.258-64%-0.048-93%0.025-2954%0.025-2954%
Usd Book Value Per Share--0.4731.078-56%1.293-63%0.876-46%0.876-46%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.735-0.387-47%-0.231-69%-0.204-72%-0.204-72%
Usd Free Cash Flow---20177000.000-19721000.000-2%-13328750.000-34%-10989578.947-46%-10989578.947-46%
Usd Free Cash Flow Per Share---0.308-0.301-2%-0.204-34%-0.168-46%-0.168-46%
Usd Free Cash Flow To Equity Per Share---0.310-0.198-36%-0.393+27%-0.038-88%-0.038-88%
Usd Market Cap13942277.100-30%18112692.903256045542.976-93%233516777.250-92%367283443.721-95%367283443.721-95%
Usd Price Per Share0.213-30%0.2773.912-93%3.568-92%5.611-95%5.611-95%
Usd Profit---48131000.000-25347500.000-47%-15203500.000-68%-13333315.789-72%-13333315.789-72%
Usd Revenue--598000.000455000.000+31%309500.000+93%479842.105+25%479842.105+25%
Usd Total Gains Per Share---0.711-0.258-64%-0.048-93%0.025-2954%0.025-2954%
 EOD+3 -5MRQTTM+6 -30YOY+10 -265Y+8 -2710Y+8 -27

3.3 Fundamental Score

Let's check the fundamental score of Lyra Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.072
Price to Book Ratio (EOD)Between0-10.450
Net Profit Margin (MRQ)Greater than0-80.487
Operating Margin (MRQ)Greater than0-29.774
Quick Ratio (MRQ)Greater than15.348
Current Ratio (MRQ)Greater than13.602
Debt to Asset Ratio (MRQ)Less than10.672
Debt to Equity Ratio (MRQ)Less than12.053
Return on Equity (MRQ)Greater than0.15-1.554
Return on Assets (MRQ)Greater than0.05-0.509
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Lyra Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.402
Ma 20Greater thanMa 500.212
Ma 50Greater thanMa 1000.233
Ma 100Greater thanMa 2000.266
OpenGreater thanClose0.209
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Lyra Therapeutics Inc

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Fundamental data was last updated by Penke on 2024-11-14 22:27:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Lyra Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -8,048.7% means that $-80.49 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Lyra Therapeutics Inc:

  • The MRQ is -8,048.7%. The company is making a huge loss. -2
  • The TTM is -6,381.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-8,048.7%TTM-6,381.7%-1,667.0%
TTM-6,381.7%YOY-35,220.0%+28,838.3%
TTM-6,381.7%5Y-13,366.6%+6,984.9%
5Y-13,366.6%10Y-13,366.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8,048.7%-112.2%-7,936.5%
TTM-6,381.7%-221.4%-6,160.3%
YOY-35,220.0%-210.0%-35,010.0%
5Y-13,366.6%-342.2%-13,024.4%
10Y-13,366.6%-464.5%-12,902.1%
4.3.1.2. Return on Assets

Shows how efficient Lyra Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • -50.9% Return on Assets means that Lyra Therapeutics Inc generated $-0.51 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Lyra Therapeutics Inc:

  • The MRQ is -50.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -22.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-50.9%TTM-22.6%-28.3%
TTM-22.6%YOY-13.7%-8.8%
TTM-22.6%5Y-15.6%-6.9%
5Y-15.6%10Y-15.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-50.9%-11.3%-39.6%
TTM-22.6%-11.7%-10.9%
YOY-13.7%-11.3%-2.4%
5Y-15.6%-12.7%-2.9%
10Y-15.6%-14.1%-1.5%
4.3.1.3. Return on Equity

Shows how efficient Lyra Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • -155.4% Return on Equity means Lyra Therapeutics Inc generated $-1.55 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Lyra Therapeutics Inc:

  • The MRQ is -155.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -55.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-155.4%TTM-55.0%-100.4%
TTM-55.0%YOY-18.5%-36.5%
TTM-55.0%5Y-26.7%-28.3%
5Y-26.7%10Y-26.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-155.4%-14.2%-141.2%
TTM-55.0%-15.9%-39.1%
YOY-18.5%-14.3%-4.2%
5Y-26.7%-18.5%-8.2%
10Y-26.7%-19.3%-7.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Lyra Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Lyra Therapeutics Inc is operating .

  • Measures how much profit Lyra Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -2,977.4% means the company generated $-29.77  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Lyra Therapeutics Inc:

  • The MRQ is -2,977.4%. The company is operating very inefficient. -2
  • The TTM is -5,441.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-2,977.4%TTM-5,441.4%+2,464.0%
TTM-5,441.4%YOY-37,265.0%+31,823.6%
TTM-5,441.4%5Y-13,616.1%+8,174.7%
5Y-13,616.1%10Y-13,616.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,977.4%-222.9%-2,754.5%
TTM-5,441.4%-310.7%-5,130.7%
YOY-37,265.0%-223.5%-37,041.5%
5Y-13,616.1%-387.1%-13,229.0%
10Y-13,616.1%-498.5%-13,117.6%
4.3.2.2. Operating Ratio

Measures how efficient Lyra Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 30.77 means that the operating costs are $30.77 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Lyra Therapeutics Inc:

  • The MRQ is 30.774. The company is inefficient in keeping operating costs low. -1
  • The TTM is 61.129. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ30.774TTM61.129-30.355
TTM61.129YOY355.865-294.736
TTM61.1295Y134.293-73.164
5Y134.29310Y134.2930.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ30.7742.465+28.309
TTM61.1293.253+57.876
YOY355.8653.298+352.567
5Y134.2934.788+129.505
10Y134.2936.494+127.799
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Lyra Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Lyra Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.60 means the company has $3.60 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Lyra Therapeutics Inc:

  • The MRQ is 3.602. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.796. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.602TTM4.796-1.193
TTM4.796YOY7.397-2.602
TTM4.7965Y8.542-3.746
5Y8.54210Y8.5420.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.6023.637-0.035
TTM4.7963.890+0.906
YOY7.3974.666+2.731
5Y8.5425.953+2.589
10Y8.5426.277+2.265
4.4.3.2. Quick Ratio

Measures if Lyra Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 5.35 means the company can pay off $5.35 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Lyra Therapeutics Inc:

  • The MRQ is 5.348. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.132. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.348TTM8.132-2.784
TTM8.132YOY10.519-2.387
TTM8.1325Y9.769-1.637
5Y9.76910Y9.7690.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3483.086+2.262
TTM8.1323.451+4.681
YOY10.5194.456+6.063
5Y9.7695.931+3.838
10Y9.7696.436+3.333
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Lyra Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Lyra Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Lyra Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.67 means that Lyra Therapeutics Inc assets are financed with 67.2% credit (debt) and the remaining percentage (100% - 67.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Lyra Therapeutics Inc:

  • The MRQ is 0.672. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.450. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.672TTM0.450+0.223
TTM0.450YOY0.249+0.201
TTM0.4505Y0.483-0.033
5Y0.48310Y0.4830.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6720.350+0.322
TTM0.4500.344+0.106
YOY0.2490.310-0.061
5Y0.4830.365+0.118
10Y0.4830.382+0.101
4.5.4.2. Debt to Equity Ratio

Measures if Lyra Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 205.3% means that company has $2.05 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Lyra Therapeutics Inc:

  • The MRQ is 2.053. The company is just not able to pay all its debts with equity.
  • The TTM is 0.976. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ2.053TTM0.976+1.077
TTM0.976YOY0.335+0.642
TTM0.9765Y0.464+0.513
5Y0.46410Y0.4640.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0530.394+1.659
TTM0.9760.432+0.544
YOY0.3350.380-0.045
5Y0.4640.451+0.013
10Y0.4640.490-0.026
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Lyra Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Lyra Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -0.09 means the investor is paying $-0.09 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Lyra Therapeutics Inc:

  • The EOD is -0.072. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.094. Based on the earnings, the company is expensive. -2
  • The TTM is -3.593. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.072MRQ-0.094+0.022
MRQ-0.094TTM-3.593+3.499
TTM-3.593YOY-3.912+0.318
TTM-3.5935Y-10.358+6.765
5Y-10.35810Y-10.3580.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.072-2.253+2.181
MRQ-0.094-2.411+2.317
TTM-3.593-3.149-0.444
YOY-3.912-3.274-0.638
5Y-10.358-6.143-4.215
10Y-10.358-6.785-3.573
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Lyra Therapeutics Inc:

  • The EOD is -0.173. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.224. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.292. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.173MRQ-0.224+0.052
MRQ-0.224TTM-3.292+3.068
TTM-3.292YOY-4.627+1.335
TTM-3.2925Y-7.095+3.803
5Y-7.09510Y-7.0950.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.173-3.009+2.836
MRQ-0.224-3.259+3.035
TTM-3.292-3.730+0.438
YOY-4.627-4.574-0.053
5Y-7.095-8.371+1.276
10Y-7.095-9.287+2.192
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Lyra Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.58 means the investor is paying $0.58 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Lyra Therapeutics Inc:

  • The EOD is 0.450. Based on the equity, the company is cheap. +2
  • The MRQ is 0.585. Based on the equity, the company is cheap. +2
  • The TTM is 3.178. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD0.450MRQ0.585-0.135
MRQ0.585TTM3.178-2.593
TTM3.178YOY2.696+0.482
TTM3.1785Y5.533-2.355
5Y5.53310Y5.5330.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.4501.979-1.529
MRQ0.5852.051-1.466
TTM3.1782.365+0.813
YOY2.6962.455+0.241
5Y5.5333.726+1.807
10Y5.5334.378+1.155
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Lyra Therapeutics Inc.

4.8.1. Institutions holding Lyra Therapeutics Inc

Institutions are holding 57.985% of the shares of Lyra Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30Perceptive Advisors LLC19.49010.08511275756200
2024-06-30Citadel Advisors Llc7.29160.00034772816192425267.5517
2024-06-30BlackRock Inc4.32340282997826780591762.8203
2024-06-30Samsara BioCapital, LLC4.24750.161278026100
2024-06-30Vanguard Group Inc2.64440173091524943416.8368
2024-06-30Morgan Stanley - Brokerage Accounts2.48020162349014947061160.6302
2024-06-30Ikarian Capital, LLC1.61450.0509105682900
2024-06-30Geode Capital Management, LLC1.15360755095395664110.0807
2024-06-30Two Sigma Advisers, LLC1.04130.0004681600537700373.6623
2024-06-30Two Sigma Investments LLC0.74990.0003490861307118167.1454
2024-06-30New York State Common Retirement Fund0.5850.00013829003829000
2024-06-30State Street Corp0.39690259820133640105.9122
2024-06-30BOOTHBAY FUND MANAGEMENT, LLC0.35550.001523267000
2024-06-30SIMPLEX TRADING, LLC0.197301291411291410
2024-06-30Clearline Capital LP0.1820.000911912800
2024-06-30Charles Schwab Investment Management Inc0.170501116091116090
2024-06-30Bank of America Corp0.1321086459-73138-45.8267
2024-06-30Northern Trust Corp0.12810838602336538.623
2024-06-30Bank of New York Mellon Corp0.1183077423774230
2024-06-30Alpine Partners VI, LLC0.07090.002246439464390
Total 47.37310.302731008856+8418312+27.1%

4.9.2. Funds holding Lyra Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31iShares Russell 2000 ETF3.54930.00092323232-5222-0.2243
2024-09-30Vanguard Total Stock Mkt Idx Inv1.5163099254300
2024-09-30Vanguard Institutional Extnd Mkt Idx Tr0.69640.000145583200
2024-10-31iShares Russell 2000 Growth ETF0.62610.00140983500
2024-08-31Fidelity Small Cap Index0.49350.0004323038-1093-0.3372
2024-09-30Fidelity Extended Market Index0.36360.0002237985-22625-8.6816
2024-09-30Vanguard Russell 2000 ETF0.33920.00052220002708713.897
2024-09-30Russell 3000 Screened Index Composite0.28520.00351867001867000
2024-09-30Schwab Small Cap Index0.17050.000411160900
2024-10-31iShares Micro-Cap ETF0.16980.003411115300
2024-09-30BlackRock Extended Equity Market K0.10880.000171229-30-0.0421
2024-09-30Fidelity Total Market Index0.09105956000
2024-09-30The Vanguard Russell 2000 Growth Index0.07550.00064943200
2024-09-30Northern Small Cap Index0.0670.000943844438440
2024-09-30Fidelity Series Total Market Index0.065904312200
2024-08-31Spartan Small Cap Index Pool0.05890.00073854610932.9183
2024-09-30LVIP SSgA Small Cap Index Std0.05790.000537900379000
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.04480.00012930400
2024-09-30NT Ext Equity Mkt Idx Fd - L0.04460.00012922600
2024-09-30Northern Trust Extended Eq Market Idx0.04460.00012922600
Total 8.86890.01355805316+267654+4.6%

5.3. Insider Transactions

Insiders are holding 0.656% of the shares of Lyra Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-10Harlan WaksalBUY250002.96
2023-05-31Nbvm Gp, LlcBUY18054162.43
2023-05-31Perceptive Advisors LlcBUY36108322.49
2022-06-10C Ann MerrifieldBUY40005.05
2022-05-16C Ann MerrifieldBUY3285
2022-05-13C Ann MerrifieldBUY35004.81
2022-04-12Edward T AndersonBUY1184834.22
2022-04-12Harlan WaksalBUY2369664.22
2022-04-12Nbvm Gp, LlcBUY23696674.22
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-06-302023-09-302023-12-312024-03-312024-06-30
Long-term Assets Other  4,3533,1107,463-6,3521,111-428683-6830



5.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets94,582
Total Liabilities63,605
Total Stockholder Equity30,977
 As reported
Total Liabilities 63,605
Total Stockholder Equity+ 30,977
Total Assets = 94,582

Assets

Total Assets94,582
Total Current Assets69,435
Long-term Assets25,147
Total Current Assets
Cash And Cash Equivalents 31,905
Short-term Investments 35,593
Other Current Assets 1,937
Total Current Assets  (as reported)69,435
Total Current Assets  (calculated)69,435
+/-0
Long-term Assets
Property Plant Equipment 23,155
Other Assets 0
Long-term Assets  (as reported)25,147
Long-term Assets  (calculated)23,155
+/- 1,992

Liabilities & Shareholders' Equity

Total Current Liabilities19,276
Long-term Liabilities44,329
Total Stockholder Equity30,977
Total Current Liabilities
Short-term Debt 4,269
Accounts payable 4,971
Other Current Liabilities 9,222
Total Current Liabilities  (as reported)19,276
Total Current Liabilities  (calculated)18,462
+/- 814
Long-term Liabilities
Capital Lease Obligations 36,748
Long-term Liabilities  (as reported)44,329
Long-term Liabilities  (calculated)36,748
+/- 7,581
Total Stockholder Equity
Common Stock65
Retained Earnings -381,938
Accumulated Other Comprehensive Income -4
Other Stockholders Equity 412,854
Total Stockholder Equity (as reported)30,977
Total Stockholder Equity (calculated)30,977
+/-0
Other
Capital Stock65
Cash and Short Term Investments 67,498
Common Stock Shares Outstanding 65,460
Current Deferred Revenue814
Liabilities and Stockholders Equity 94,582
Net Debt 4,843
Net Invested Capital 30,977
Net Working Capital 50,159
Property Plant and Equipment Gross 23,155
Short Long Term Debt Total 36,748



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
0
0
14,963
40,766
92,723
87,330
80,830
72,917
76,332
67,762
54,867
47,345
130,035
119,463
109,968
93,868
125,675
120,575
142,600
141,527
94,582
94,582141,527142,600120,575125,67593,868109,968119,463130,03547,34554,86767,76276,33272,91780,83087,33092,72340,76614,963000
   > Total Current Assets 
0
0
0
10,119
35,540
89,310
83,555
75,917
67,351
70,073
60,886
47,918
40,555
122,381
112,230
100,829
84,799
118,253
104,920
104,821
89,443
69,435
69,43589,443104,821104,920118,25384,799100,829112,230122,38140,55547,91860,88670,07367,35175,91783,55589,31035,54010,119000
       Cash And Cash Equivalents 
0
0
0
9,808
35,247
86,599
81,555
74,593
66,105
69,046
58,131
45,747
33,755
120,669
109,558
32,550
22,019
54,361
24,850
22,353
15,799
31,905
31,90515,79922,35324,85054,36122,01932,550109,558120,66933,75545,74758,13169,04666,10574,59381,55586,59935,2479,808000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
65,344
60,688
61,789
77,700
80,400
71,319
35,593
35,59371,31980,40077,70061,78960,68865,344000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
5,000
0
0
0
0
0
0
0
0
0
0000000005,000000000000000
       Other Current Assets 
0
0
0
311
293
2,711
2,000
1,324
1,246
1,027
2,755
2,171
1,800
1,383
2,343
2,935
2,092
1,800
2,370
2,068
2,325
1,937
1,9372,3252,0682,3701,8002,0922,9352,3431,3831,8002,1712,7551,0271,2461,3242,0002,711293311000
   > Long-term Assets 
0
0
0
4,844
5,226
3,413
3,775
4,913
5,566
6,259
6,876
6,949
6,790
7,654
7,233
9,139
9,069
7,422
15,655
37,779
52,084
25,147
25,14752,08437,77915,6557,4229,0699,1397,2337,6546,7906,9496,8766,2595,5664,9133,7753,4135,2264,844000
       Property Plant Equipment 
0
0
0
3,419
3,247
3,084
3,446
4,466
5,237
5,687
6,302
5,858
5,384
4,869
4,361
4,466
3,829
1,980
6,800
35,276
49,409
23,155
23,15549,40935,2766,8001,9803,8294,4664,3614,8695,3845,8586,3025,6875,2374,4663,4463,0843,2473,419000
       Other Assets 
0
0
0
0
1,979
329
329
2,748
329
572
574
1,091
1,406
2,785
2,872
4,673
0
5,442
0
0
0
0
00005,44204,6732,8722,7851,4061,0915745723292,7483293291,9790000
> Total Liabilities 
0
0
0
7,635
167,547
5,900
6,416
6,338
5,366
18,833
20,574
20,551
19,189
19,005
26,241
29,214
27,777
27,098
36,336
53,180
64,023
63,605
63,60564,02353,18036,33627,09827,77729,21426,24119,00519,18920,55120,57418,8335,3666,3386,4165,900167,5477,635000
   > Total Current Liabilities 
0
0
0
5,208
5,158
3,942
4,708
4,884
4,170
5,904
17,773
18,246
17,802
9,872
13,605
14,470
14,154
14,111
19,235
19,597
18,724
19,276
19,27618,72419,59719,23514,11114,15414,47013,6059,87217,80218,24617,7735,9044,1704,8844,7083,9425,1585,208000
       Short-term Debt 
0
0
0
899
919
943
964
985
1,007
1,029
1,052
1,074
1,097
926
654
1,549
1,900
1,688
1,403
5,434
4,504
4,269
4,2694,5045,4341,4031,6881,9001,5496549261,0971,0741,0521,0291,007985964943919899000
       Accounts payable 
0
0
0
1,069
1,358
1,146
530
922
1,169
1,899
2,912
3,125
2,408
1,670
2,900
2,616
3,951
4,188
5,054
3,131
2,844
4,971
4,9712,8443,1315,0544,1883,9512,6162,9001,6702,4083,1252,9121,8991,1699225301,1461,3581,069000
       Other Current Liabilities 
0
0
0
110
153
109
109
149
63
-9,024
3,968
4,258
4,237
5,465
7,321
9,030
6,793
6,738
11,052
9,374
10,057
9,222
9,22210,0579,37411,0526,7386,7939,0307,3215,4654,2374,2583,968-9,02463149109109153110000
   > Long-term Liabilities 
0
0
0
2,427
162,389
1,958
1,708
1,454
1,196
12,929
2,801
2,305
1,387
9,133
12,636
14,744
13,623
12,987
17,101
33,583
45,299
44,329
44,32945,29933,58317,10112,98713,62314,74412,6369,1331,3872,3052,80112,9291,1961,4541,7081,958162,3892,427000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
12,000
2,145
1,926
1,288
9,130
12,633
14,077
0
12,987
0
0
0
0
000012,987014,07712,6339,1301,2881,9262,14512,000000000000
       Deferred Long Term Liability 
0
0
0
0
1,650
0
0
0
0
12,000
0
0
1,288
9,130
13,176
0
13,432
0
0
0
0
0
0000013,432013,1769,1301,2880012,00000001,6500000
> Total Stockholder Equity
0
0
0
7,328
-126,781
86,823
80,914
74,492
67,551
57,499
47,188
34,316
28,156
111,030
93,222
80,754
66,091
98,577
84,239
89,420
77,504
30,977
30,97777,50489,42084,23998,57766,09180,75493,222111,03028,15634,31647,18857,49967,55174,49280,91486,823-126,7817,328000
   Common Stock
0
0
0
6
-39,742
13
13
13
13
13
13
13
13
32
32
32
32
50
50
57
61
65
6561575050323232321313131313131313-39,7426000
   Retained Earnings Total Equity00000-264,9300-219,674-214,893-200,40900-168,725-157,686-149,8840000000
   Accumulated Other Comprehensive Income 
0
0
0
-2,829
-2,837
-2,850
-87,330
0
0
0
0
0
0
0
0
10
-12
-27
-7
33
25
-4
-42533-7-27-121000000000-87,330-2,850-2,837-2,829000
   Capital Surplus 
0
0
0
0
5,208
0
0
224,363
225,224
226,211
0
0
228,552
325,891
325,891
0
331,001
0
0
0
0
0
00000331,0010325,891325,891228,55200226,211225,224224,363005,2080000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
0
0
0
137,908
8,045
133,466
223,764
224,363
225,224
226,211
226,955
227,700
228,552
325,891
327,630
329,387
331,001
379,102
380,395
400,685
411,225
412,854
412,854411,225400,685380,395379,102331,001329,387327,630325,891228,552227,700226,955226,211225,224224,363223,764133,4668,045137,908000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue1,558
Cost of Revenue-278
Gross Profit1,2801,280
 
Operating Income (+$)
Gross Profit1,280
Operating Expense-66,808
Operating Income-65,528-65,528
 
Operating Expense (+$)
Research Development47,751
Selling General Administrative19,057
Selling And Marketing Expenses0
Operating Expense66,80866,808
 
Net Interest Income (+$)
Interest Income4,094
Interest Expense-0
Other Finance Cost-0
Net Interest Income4,094
 
Pretax Income (+$)
Operating Income-65,528
Net Interest Income4,094
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-62,621-68,435
EBIT - interestExpense = -65,528
-62,621
-62,680
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-65,528-62,621
Earnings Before Interest and Taxes (EBITDA)-65,250
 
After tax Income (+$)
Income Before Tax-62,621
Tax Provision-55
Net Income From Continuing Ops-61,759-62,676
Net Income-62,680
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses67,086
Total Other Income/Expenses Net2,907-4,094
 

Technical Analysis of Lyra Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Lyra Therapeutics Inc. The general trend of Lyra Therapeutics Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Lyra Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Lyra Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.2105 < 0.2799 < 0.28.

The bearish price targets are: 0.1625.

Tweet this
Lyra Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Lyra Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Lyra Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Lyra Therapeutics Inc. The current macd is -0.01097643.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Lyra Therapeutics Inc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Lyra Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Lyra Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Lyra Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartLyra Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Lyra Therapeutics Inc. The current adx is 20.18.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Lyra Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Lyra Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Lyra Therapeutics Inc. The current sar is 0.166304.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Lyra Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Lyra Therapeutics Inc. The current rsi is 48.40. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Lyra Therapeutics Inc Daily Relative Strength Index (RSI) ChartLyra Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Lyra Therapeutics Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Lyra Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Lyra Therapeutics Inc Daily Stochastic Oscillator ChartLyra Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Lyra Therapeutics Inc. The current cci is 5.79647264.

Lyra Therapeutics Inc Daily Commodity Channel Index (CCI) ChartLyra Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Lyra Therapeutics Inc. The current cmo is 4.88088366.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Lyra Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartLyra Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Lyra Therapeutics Inc. The current willr is -30.34482759.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Lyra Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Lyra Therapeutics Inc Daily Williams %R ChartLyra Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Lyra Therapeutics Inc.

Lyra Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Lyra Therapeutics Inc. The current atr is 0.02292198.

Lyra Therapeutics Inc Daily Average True Range (ATR) ChartLyra Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Lyra Therapeutics Inc. The current obv is -131,098,285.

Lyra Therapeutics Inc Daily On-Balance Volume (OBV) ChartLyra Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Lyra Therapeutics Inc. The current mfi is 54.60.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Lyra Therapeutics Inc Daily Money Flow Index (MFI) ChartLyra Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Lyra Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-29STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-08-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-08-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-20MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-27STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Lyra Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Lyra Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.402
Ma 20Greater thanMa 500.212
Ma 50Greater thanMa 1000.233
Ma 100Greater thanMa 2000.266
OpenGreater thanClose0.209
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Lyra Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Lyra Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Lyra Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Lyra Therapeutics Inc

I send you an email if I find something interesting about Lyra Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Lyra Therapeutics Inc.

Receive notifications about Lyra Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.